The Berwyn drug developer is conducting a phase 2/3 clinical trial to test its lead drug candidate buntanetap as a treatment for mild to moderate Alzheimer’s disease.
The Berwyn drug developer is conducting a phase 2/3 clinical trial to test its lead drug candidate buntanetap as a treatment for mild to moderate Alzheimer’s disease.
